12 Month Price Forecast For MDWD
Distance to MDWD Price Forecasts
MDWD Price Momentum
๐ค Considering MediWound (MDWD)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 5, 2025 12:47 PM UTC
MDWD Analyst Ratings & Price Targets
Based on our analysis of 9 Wall Street analysts, MDWD has a consensus that is bullish. The median price target is $27.50, with forecasts ranging from $25.00 to $36.00. Currently, there are 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With MDWD currently trading at $19.50, the median price forecast suggests a 41.0% upside. The most optimistic forecast comes from at , projecting a 84.6% upside, while Swayampakula Ramakanth at HC Wainwright & Co. provides the most conservative target, suggesting a 28.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MDWD Analyst Consensus
MDWD Price Target Range
Latest MDWD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MDWD.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Jan 10, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $25.00 |
Nov 27, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $25.00 |
Oct 11, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $28.00 |
Aug 15, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $28.00 |
Jul 16, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $28.00 |
May 30, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $28.00 |
Mar 22, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $28.00 |
Jan 16, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $28.00 |
Nov 22, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $26.00 |
Sep 21, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $26.00 |
Aug 17, 2023 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
Aug 17, 2023 | Oppenheimer | Outperform | Maintains | $0.00 | |
May 31, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $23.00 |
May 31, 2023 | Oppenheimer | Francois Brisebois | Outperform | Reiterates | $63.00 |
Mar 17, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $23.00 |
Jan 4, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $23.00 |
Dec 30, 2022 | Cowen & Co. | Joshua Jennings | Outperform | Maintains | $25.00 |
Dec 22, 2022 | Maxim Group | Michael Okunewitch | Buy | Initiates | $25.00 |
Dec 21, 2022 | Oppenheimer | Francois Brisebois | Outperform | Maintains | $63.00 |
Nov 16, 2022 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $5.50 |
Stocks Similar to MediWound Ltd
The following stocks are similar to MediWound based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
MediWound Ltd (MDWD) Financial Data
MediWound Ltd has a market capitalization of $210.40M with a P/E ratio of -26.0x. The company generates $20.14M in trailing twelve-month revenue with a -99.2% profit margin.
Revenue growth is +6.1% quarter-over-quarter, while maintaining an operating margin of -88.6% and return on equity of -75.7%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

MediWound Ltd (MDWD) Company Overview
About MediWound Ltd
Develops biopharmaceutical solutions for tissue repair.
MediWound Ltd. generates revenue by developing and commercializing bio-therapeutic products aimed at tissue repair and regeneration. Its primary product, NexoBrid, is marketed to burn centers and hospitals for the treatment of thermal burns, while additional products like EscharEx and MW005 are in various stages of clinical development, targeting chronic wounds and cancer treatment respectively.
Founded in 2000 and headquartered in Yavne, Israel, MediWound operates in the biopharmaceutical sector with a focus on innovative solutions for wound care and tissue regeneration, addressing significant medical needs in both acute and chronic conditions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
100
CEO
Country
Israel
IPO Year
2014
Website
www.mediwound.comMediWound Ltd (MDWD) Latest News & Analysis
MediWound (MDWD) shares rose with above-average trading volume, but recent earnings estimate revisions may not lead to further price increases soon.
MediWound's share surge and above-average trading volume indicate heightened investor interest, but revised earnings estimates suggest potential price stabilization ahead.
MediWound Ltd. (NASDAQ:MDWD) will hold its Q3 2024 Earnings Conference Call on November 26, 2024, at 8:30 AM ET, featuring key executives and analysts.
The earnings call on November 26 will provide insights into MediWound's financial health and strategic direction, influencing stock performance and investor sentiment.
MediWound Ltd. plans to submit an IND for EscharEx by year-end and start a Phase 3 study. FDA approved NexoBrid for pediatric use, with strong product demand and financing to support operations.
MediWound's IND submission and FDA approval for NexoBrid enhance growth prospects, while financing boosts cash flow, signaling potential profitability and strong demand for its products.
MediWound (MDWD) reported a quarterly loss of $0.98 per share, wider than the estimated loss of $0.48, compared to a loss of $0.24 per share a year earlier.
MediWound's larger-than-expected loss signals potential operational challenges, raising concerns about its financial health and future profitability, impacting investor confidence and stock performance.
MediWound Is A Healthy Investment
3 months agoMediWound (MDWD) is seen as a long-term buy due to its innovative products and expected revenue growth, despite current losses. It has nearly doubled in price YTD and has strong investor backing.
MediWound presents a potential growth opportunity despite current losses. Strong revenue projections, institutional backing, and a booming industry enhance its appeal to investors.
The company has secured new R&D collaborations with Solventum and Mรถlnlycke to enhance trial consistency and improve patient outcomes.
New R&D collaborations can enhance product development, improve trial results, and potentially lead to market advantages, positively impacting future revenue and stock performance.
Frequently Asked Questions About MDWD Stock
What is MediWound Ltd's (MDWD) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, MediWound Ltd (MDWD) has a median price target of $27.50. The highest price target is $36.00 and the lowest is $25.00.
Is MDWD stock a good investment in 2025?
According to current analyst ratings, MDWD has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $19.50. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for MDWD stock?
Wall Street analysts predict MDWD stock could reach $27.50 in the next 12 months. This represents a 41.0% increase from the current price of $19.50. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is MediWound Ltd's business model?
MediWound Ltd. generates revenue by developing and commercializing bio-therapeutic products aimed at tissue repair and regeneration. Its primary product, NexoBrid, is marketed to burn centers and hospitals for the treatment of thermal burns, while additional products like EscharEx and MW005 are in various stages of clinical development, targeting chronic wounds and cancer treatment respectively.
What is the highest forecasted price for MDWD MediWound Ltd?
The highest price target for MDWD is $36.00 from at , which represents a 84.6% increase from the current price of $19.50.
What is the lowest forecasted price for MDWD MediWound Ltd?
The lowest price target for MDWD is $25.00 from Swayampakula Ramakanth at HC Wainwright & Co., which represents a 28.2% increase from the current price of $19.50.
What is the overall MDWD consensus from analysts for MediWound Ltd?
The overall analyst consensus for MDWD is bullish. Out of 9 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $27.50.
How accurate are MDWD stock price projections?
Stock price projections, including those for MediWound Ltd, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.